Breaking News

Crown Bioscience Names Global Scientific Director

January 14, 2016

Murphy to oversee translational oncology research

Eric Murphy, Ph.D., has been appointed global scientific director for translational oncology at Crown Bioscience.

Most recently, Dr. Murphy designed and implemented a screening operation for a biotechnology company focused on regenerative medicine that led to phenotypic screening and compound profiling to support both discovery and translational research programs. The unit also performed translational research for clinical programs for cancer, osteoarthritis and alopecia.

Working for a large global pharmaceutical company, he employed numerous in vivo efficacy studies to identify new targets and in vitro high throughput phenotypic screens to identify new chemical starting points while building an extensive network of academic collaborations to perform translational and drug discovery research.

“For more than 20 years, Dr. Murphy has focused on translational and drug discovery research for some of the most respected academic and biopharmaceutical organizations in the world,” said Laurie Heilmann, senior vice president of global strategy, marketing and business development at Crown Bioscience. “Working with our innovative research and development teams to leverage our scientific platforms, he will assist clients with early preclinical studies and support clinical development strategies to translate new cancer therapeutics.”

  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Cryogenic Cold Chain Risk Mitigation

    Cryogenic Cold Chain Risk Mitigation

    Kristin Brooks, Contract Pharma||November 13, 2015
    Mark Sawicki of Cryoport explains the requirements, challenges, and regulatory aspects around cryogenic logistics

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research